MarketCap
Facebook
X
Telegram
Viatris Cost of Revenue | VTRS
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Viatris
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.29 B | 9.12 B | 8.99 B | 9.77 B | 12.3 B | 8.15 B | 7.6 B | 7.43 B | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.3 B | 7.43 B | 9.08 B |
Quarterly Cost of Revenue Viatris
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.36 B | 2.39 B | 2.25 B | 2.09 B | 2.29 B | 2.35 B | 2.16 B | 2.25 B | 2.31 B | 2.19 B | - | 2.33 B | 2.41 B | 2.42 B | - | 2.96 B | 3.25 B | 3.3 B | - | 1.81 B | 1.71 B | 1.71 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.3 B | 1.71 B | 2.34 B |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
60.5 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
5.82 M | - | 7.5 % | $ 6.35 M |  USA |
 |
DURECT Corporation
DRRX
|
78 K | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Jupiter Wellness
JUPW
|
2.69 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
Assertio Holdings
ASRT
|
35.4 M | - | - | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
2.96 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
7.23 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Zomedica Corp.
ZOM
|
10.4 M | - | -0.21 % | $ 98 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.42 | -1.39 % | $ 3.37 M |  Canada |
 |
Canopy Growth Corporation
CGC
|
215 M | $ 0.97 | 2.49 % | $ 289 M | Canada |
 |
China Pharma Holdings
CPHI
|
4.28 M | $ 0.77 | -6.56 % | $ 3.3 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
6.67 M | $ 5.72 | 1.96 % | $ 85 M | USA |
 |
Emergent BioSolutions
EBS
|
326 M | $ 8.0 | -1.72 % | $ 428 M | USA |
 |
Evolus
EOLS
|
100 M | $ 6.63 | -1.63 % | $ 427 M | USA |
 |
Harrow Health
HROW
|
67.9 M | $ 42.87 | 2.22 % | $ 1.58 B | USA |
 |
OrganiGram Holdings
OGI
|
111 M | $ 0.96 | -2.28 % | $ 91.5 M | Canada |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 2.44 | 4.27 % | $ 309 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 22.33 | -1.37 % | $ 1.03 B | USA |
 |
Perrigo Company plc
PRGO
|
2.76 B | $ 10.25 | 0.89 % | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 6.73 | 1.97 % | $ 266 M | USA |
 |
Rockwell Medical
RMTI
|
57.6 M | $ 0.64 | -1.61 % | $ 23 M | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 4.05 | 6.58 % | $ 202 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
12.1 M | $ 1.15 | - | $ 1.94 M | USA |
 |
Tilray
TLRY
|
480 M | $ 4.73 | -0.42 % | $ 2.92 B | Canada |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 1.95 | -14.1 % | $ 22.6 M | USA |
 |
Veru
VERU
|
11 M | $ 2.95 | -1.34 % | $ 43.2 M | USA |